Search results
Evotec and Pfizer announce drug discovery collaboration
Pharmaceutical Technology· 35 minutes agoEvotec and Pfizer have entered a multi-year partnership that will focus initially on early discovery...
Pfizer research chief Dolsten to step down, with company at a crossroads
BioPharma Dive· 1 day agoThe company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and...
Pfizer's chief scientist Mikael Dolsten to step down - ET HealthWorld | Pharma
The Economic Times· 9 hours agoLondon: Pfizer said on Tuesday Chief Scientific Officer Mikael Dolsten, a key figure behind the...
Pfizer's key scientist Mikael Dolsten, who developed Covid vaccine, to step down - Times of India
The Times of India· 22 hours agoUS pharmaceutical giant Pfizer on Tuesday said its chief scientific officer Mikael Dolsten, a key...
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births - ET HealthWorld |...
The Economic Times· 1 day agoLondon: Pfizer's respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a...
UK pharma group reprimands Novo Nordisk for undisclosed payments
Pharmaceutical Technology· 2 days agoThe Association of the British Pharmaceutical Industry (ABPI) has pulled up four pharmaceutical...
Top Gainers and Losers today on 10 July, 2024: Asian Paints, SBI Life Insurance Company, Mahindra &...
Livemint· 35 minutes agoTop Gainers and Losers Today : The Sensex lost 426.87 points, or -0.53, to settle at 80351.64, while...
Moneycontrol Pro Panorama | Pharma companies step up R&D spends to climb product ladder
CNBC Awaaz· 1 day agoThe Panorama newsletter is sent to Moneycontrol Pro subscribers on market days. It offers easy...
Should investors hold Emcure Pharma for long term? Sneha Poddar answers
The Economic Times· 3 hours agoCan you tell us a little bit more about the business of Emcure Pharma? Sneha Poddar: So, Emcure is...
iOnctura expands PI3K inhibitor programme to NSCLC
Pharmaceutical Technology· 18 hours agoRoche made a recent advancement in the space, securing FDA priority review in breast cancer for the PI3K inhibitor inavolisib as a combination therapy...